Allogene Therapeutics (ALLO) Receivables - Other (2020 - 2023)

Allogene Therapeutics (ALLO) has 4 years of Receivables - Other data on file, last reported at $1.2 million in Q1 2023.

• For the quarter ending Q1 2023, Receivables - Other fell 87.23% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2023 stood at $1.2 million (down 87.23% YoY), and the FY2022 full-year result was $1.5 million, down 63.41% from the prior year.
• Receivables - Other eased to $1.2 million in Q1 2023, from $1.5 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $10.2 million in Q2 2022 to a low of $1.2 million in Q1 2023.
• A 4-year average of $5.2 million and a median of $4.2 million in 2021 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other jumped 142.86% in 2022 and plunged 87.23% in 2023, its largest moves.
• Tracing ALLO's Receivables - Other over 4 years: stood at $3.8 million in 2020, then increased by 7.89% to $4.1 million in 2021, then tumbled by 63.41% to $1.5 million in 2022, then fell by 20.0% to $1.2 million in 2023.
• Business Quant data shows ALLO's Receivables - Other at $1.2 million in Q1 2023, $1.5 million in Q4 2022, and $4.3 million in Q3 2022.